Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9603 posts found.

Merck acquires eyecare specialist Inspire

April 6, 2011 Research and Development, Sales and Marketing Inspire, Merck, eye care

Merck & Co is to buy ophthalmic specialist Inspire Pharmaceuticals in a $430 million deal which sees it move further …
News
Boehringer Andreas Barner

Boehringer bets on Pradaxa to fill portfolio gaps

April 6, 2011 Research and Development, Sales and Marketing Boehringer, Boehringer Ingelheim, Pradaxa

Boehringer Ingelheim has identified Pradaxa as one of the cornerstones of its “new growth phase” as the manufacturer seeks to …
News
pfizer_belgium_kris_westelinck

Kris Westelinck appointed president of Pfizer Belgium

April 5, 2011 Manufacturing and Production, Research and Development, Sales and Marketing appointment, manufacturing and production, researcha and development, sales and marketing

Pfizer Belgium has promoted Kris Westelinck to the role of president. Kris was previously managing director and head of Pfizer’s …
Appointment

ABPI appoints new head

April 5, 2011 Manufacturing and Production, Research and Development, Sales and Marketing ABPI, appointment

The ABPI has appointed former Prudential communications director Stephen Whitehead as its new head. He joins the UK pharma industry …
News

New BMS drug trumps peg-interferon alpha

April 4, 2011 Research and Development, Sales and Marketing BMS, EASL, hepatitis C, pegintron alfa

Bristol-Myers Squibb has been given a boost by trial results which suggest its compound for hepatitis C, PEG-Interferon lambda, is …
News

Angela Pasma to lead Chiltern’s new Netherlands office

April 1, 2011 Research and Development appointment, chiltern, research and development

Contract research organisation Chiltern has expanded its European operations, opening a new office in the Netherlands. The Leiden office will …
Appointment
Amgen

Amgen’s novel lung cancer drug disappoints in phase III

April 1, 2011 Research and Development Amgen, Millennium, NSCLC, Takeda, motesanib, non-small cell lung cancer

Amgen’s lung cancer drug motesanib has not meet its primary endpoint in a phase III study. The drug, developed in …
News
GlaxoSmitKline

GSK details $28.5m of research payments to US institutions

April 1, 2011 Research and Development GSK, payments

GlaxoSmithKline has made public the payments it gave last year to US institutions engaged in clinical research on its behalf. …
News

TcL Pharma appoints French pharma veterans

April 1, 2011 Research and Development, Sales and Marketing TcL, appointment, biotech, recruitment

TcL Pharma has appointed two seasoned veterans of the French pharmaceutical industry. Dr Jean-Hugues Masgnaux joins the French biotech company …
News
Cephalon

Valeant makes $5.7 billion hostile bid for Cephalon

March 31, 2011 Research and Development, Sales and Marketing Cephalon, Valeant

Valeant has made a hostile bid for Cephalon, but analysts believe its offer is too low for the deal to …
News

Roche appoints Janet Hammond to translational medicine role

March 31, 2011 Research and Development appointment, research and development

Janet Hammond has joined Roche to drive the early clinical development strategy for its virology discovery and translational area. She …
Appointment

EU Clinical Trials Register is Launched

March 29, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates

The European Medicines Agency (EMA) has announced the launch of its EU Clinical Trials Register. This online register allows public …
News
Press release

Chiltern Expands European Operations with a New Office in The Netherlands

March 29, 2011 Research and Development

Chiltern International Limited (Chiltern), a global clinical contract research organization (CRO) announced that it has opened a new office in …
News
Press release

Telaprevir to be added to standard hep C therapy

March 27, 2011 Research and Development, Sales and Marketing hepatitis C, telaprevir

Telaprevir – currently being co-developed by Vertex, Johnson & Johnson and Mitsubishi Tanabe  – will become part of a standard …
News

GSK withdraws applications for Avodart

March 25, 2011 Research and Development Avodart, Cancer, GSK, bph, prostate cancer

GlaxoSmithKline has withdrawn all regulatory applications for Avodart to prevent prostate cancer after regulators raised doubts about its benefit/risk profile. …
News
The Gateway to Local Adoption Series

Latest content

Thermo Fisher opens new distribution centre in Ireland

March 12, 2026

Altimetrik appoints Dhirendra Nath as Chief Human Resources Officer

March 12, 2026

Kindeva appoints Mike Cowhig as Chief Legal Officer

March 11, 2026

DiaMedica gets regulatory clearance from Health Canada for phase 2 preeclampsia study

March 11, 2026

Abselion establishes a US subsidiary in Massachusetts 

March 10, 2026